Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00924807 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer
A Phase 1 study, sponsored by Beth Israel Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT00924807 is a Phase 1 study that was terminated before completion, run by Beth Israel Medical Center. The registered enrollment target is 4 participants.
The verdict
NCT00924807, a Phase 1 study, was terminated before completion, sponsored by Beth Israel Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of a new drug- sorafenib, which is to be administered at the same time as standard treatment, which includes hormonal therapy and external beam radiotherapy.
Interventions
- DRUG Leuprolide acetate, Bicalutamide, Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2008-09 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00924807
The ClinicalTrials.gov registry entry for NCT00924807 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Medical Center, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Leuprolide acetate, Bicalutamide, Sorafenib is the first listed.
NCT00924807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00924807 about?
NCT00924807 is a clinical study titled "Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer". The purpose of this study is to evaluate the safety of a new drug- sorafenib, which is to be administered at the same time as standard treatment, which includes hormonal therapy and external beam radiotherapy.
What is the current status of trial NCT00924807?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2008-09. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00924807?
The interventions under investigation include: Leuprolide acetate, Bicalutamide, Sorafenib (DRUG).
Who is sponsoring clinical trial NCT00924807?
This trial is sponsored by Beth Israel Medical Center, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.